XENPOZYME
Live / Registered — Registered (as of 17 Jan 2023)
What this means for you
Registered since 17 Jan 2023. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 17 Jan 2029: the §8 declaration of use).
Record
- Serial number
- 88330513
- Registration number
- 6957890
- Mark type
- Word mark
- Filed
- 07 Mar 2019
- Published for opposition
- 17 Sept 2019
- Registered
- 17 Jan 2023
- Next maintenance filing
- §8 declaration of use, due by 17 Jan 2029 (grace period to 17 Jul 2029)
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare diseases; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 17 Jan 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Jan 2023 — REGISTERED-PRINCIPAL REGISTER
- 14 Dec 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 13 Dec 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 28 Sept 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 23 Sept 2022 — USE AMENDMENT FILED
- 23 Sept 2022 — TEAS STATEMENT OF USE RECEIVED
- 09 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Apr 2022 — SOU EXTENSION 5 GRANTED
- 04 Apr 2022 — SOU EXTENSION 5 FILED
- 08 Apr 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Apr 2022 — SOU TEAS EXTENSION RECEIVED
- 15 Oct 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Oct 2021 — SOU EXTENSION 4 GRANTED
- 13 Oct 2021 — SOU EXTENSION 4 FILED